Sign In
Buy BIO
$301.90
-2.46 (-0.81%)
At Close: Jul 20, 2026
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
04:15pm, Thursday, 17'th Jul 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
09:10am, Monday, 14'th Jul 2025
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
New Strong Sell Stocks for July 10th
06:21am, Thursday, 10'th Jul 2025
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
09:00am, Monday, 07'th Jul 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new
International Defense Ministry Awards BIO-key over $600K in Follow-On Orders for Secure Biometric Access to Critical Information
07:58am, Tuesday, 17'th Jun 2025
International Defense Ministry Awards BIO-key (Nasdaq: BKYI) over $600K in Follow-On Orders for Secure Biometric Access to Critical Information #Biometrics
Enveric Biosciences Announces Participation in 2025 BIO International Convention
10:46am, Monday, 16'th Jun 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecul
FibroBiologics to Present at the BIO International Convention 2025
09:50am, Monday, 16'th Jun 2025
HOUSTON, June 16, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the d
Hoth Therapeutics to Attend 2025 BIO International Convention
08:00am, Monday, 16'th Jun 2025
NEW YORK , June 16, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, pioneering breakthrough therapies to improve the lives of patients, today a
Aptevo Participating in the BIO International Convention
08:05am, Friday, 13'th Jun 2025
SEATTLE, WA / ACCESS Newswire / June 13, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its pro
Grace Therapeutics to Participate in the 2025 BIO International Conference
08:00am, Friday, 13'th Jun 2025
PRINCETON, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, nov
Rakovina Therapeutics to Attend BIO International Convention to Advance Strategic Partnering Opportunities
08:30am, Thursday, 12'th Jun 2025
VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovativ
Werewolf Therapeutics to Participate in the BIO International Convention
08:00am, Thursday, 12'th Jun 2025
WATERTOWN, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development
Niagen Bioscience to Participate in the BIO 2025 International Convention
08:31am, Wednesday, 11'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the
Lisata Therapeutics to Present at the 2025 BIO International Convention
08:30am, Wednesday, 11'th Jun 2025
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative thera
Castle Biosciences' Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention
07:00am, Wednesday, 11'th Jun 2025
FRIENDSWOOD, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek
